BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32827632)

  • 1. Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.
    Le Page C; Amuzu S; Rahimi K; Gotlieb W; Ragoussis J; Tonin PN
    Semin Cancer Biol; 2021 Dec; 77():110-126. PubMed ID: 32827632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
    Meghani K; Fuchs W; Detappe A; Drané P; Gogola E; Rottenberg S; Jonkers J; Matulonis U; Swisher EM; Konstantinopoulos PA; Chowdhury D
    Cell Rep; 2018 Apr; 23(1):100-111. PubMed ID: 29617652
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM
    Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
    Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer.
    Kim YN; Shim Y; Seo J; Choi Z; Lee YJ; Shin S; Kim SW; Kim S; Choi JR; Lee JY; Lee ST
    Clin Cancer Res; 2023 Jul; 29(14):2725-2734. PubMed ID: 37067525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 17. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
    Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.